|
|
||||||||
HIGH-RISK PREGNANCY SERIES: AN EXPERT'S VIEW |
From the Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.
Address reprint requests to: Brian M. Mercer, MD, MetroHealth Medical Center, Department of Obstetrics and Gynecology, 2500 MetroHealth Drive, Suite G240, Cleveland, OH 44109-1989.
Preterm premature rupture of membranes (PROM) affects over 120,000 pregnancies annually in the United States and is associated with significant maternal, fetal, and neonatal risk. Management of PROM requires an accurate diagnosis as well as evaluation of the risks and benefits of continued pregnancy or expeditious delivery. An understanding of gestational agedependent neonatal morbidity and mortality is important in determining the potential benefits of conservative management of preterm PROM at any gestation. Where possible, the treatment of pregnancies complicated by PROM remote from term should be directed towards conserving the pregnancy and reducing perinatal morbidity due to prematurity while monitoring closely for evidence of infection, placental abruption, labor, or fetal compromise due to umbilical cord compression. Current evidence suggests aggressive adjunctive antibiotic therapy to reduce gestational agedependent and infectious infant morbidity. Similarly, review of evaluable data indicates that antenatal corticosteroid administration in this setting enhances neonatal outcome without increasing the risk of perinatal infection. It is not clear that tocolysis in the setting of preterm PROM remote from term reduces infant morbidity. When preterm PROM occurs near term, particularly if fetal pulmonary maturity is evident, the patient is generally best served by expeditious delivery.
This article has been cited by other articles:
![]() |
S. E. CALVIN and M. L. OYEN Microstructure and Mechanics of the Chorioamnion Membrane with an Emphasis on Fracture Properties Ann. N.Y. Acad. Sci., April 1, 2007; 1101(1): 166 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Murtha, T. Sinclair, E. R. Hauser, G. K. Swamy, W. N. P. Herbert, and R. P. Heine Maternal Serum Cytokines in Preterm Premature Rupture of Membranes Obstet. Gynecol., January 1, 2007; 109(1): 121 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Briggs and S. R. Wan Drug therapy during labor and delivery, part 1. Am. J. Health Syst. Pharm., June 1, 2006; 63(11): 1038 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kumar, W. Fung, R. M. Moore, V. Pandey, J. Fox, B. Stetzer, J. M. Mansour, B. M. Mercer, R. W. Redline, and J. J. Moore Proinflammatory Cytokines Found in Amniotic Fluid Induce Collagen Remodeling, Apoptosis, and Biophysical Weakening of Cultured Human Fetal Membranes Biol Reprod, January 1, 2006; 74(1): 29 - 34. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Oger, C. Mehats, E. Dallot, D. Cabrol, and M.-J. Leroy Evidence for a Role of Phosphodiesterase 4 in Lipopolysaccharide-Stimulated Prostaglandin E2 Production and Matrix Metalloproteinase-9 Activity in Human Amniochorionic Membranes J. Immunol., June 15, 2005; 174(12): 8082 - 8089. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Spinillo, L. Montanari, P. Sanpaolo, C. Bergante, A. Chiara, and E. Fazzi Fetal Growth and Infant Neurodevelopmental Outcome After Preterm Premature Rupture of Membranes Obstet. Gynecol., June 1, 2004; 103(6): 1286 - 1293. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |